The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In other words, the price has increased by $0.00 from its previous closing price. On the day, 0.57 million shares were traded. ARDT stock price reached its highest trading level at $14.555 during the session, while it also had its lowest trading level at $13.95.
Ratios:
For a deeper understanding of Ardent Health Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.72 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.18. For the most recent quarter (mrq), Quick Ratio is recorded 2.00 and its Current Ratio is at 2.13. In the meantime, Its Debt-to-Equity ratio is 1.81 whereas as Long-Term Debt/Eq ratio is at 1.79.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Goldman on October 14, 2025, initiated with a Neutral rating and assigned the stock a target price of $19.
On September 10, 2025, UBS started tracking the stock assigning a Buy rating and target price of $17.
BofA Securities Downgraded its Neutral to Underperform on July 16, 2025, while the target price for the stock was maintained at $14.60.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARDT now has a Market Capitalization of 2010645632 and an Enterprise Value of 4129017600. As of this moment, Ardent’s Price-to-Earnings (P/E) ratio for their current fiscal year is 7.83, and their Forward P/E ratio for the next fiscal year is 7.20. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.72. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.32 while its Price-to-Book (P/B) ratio in mrq is 1.60. Its current Enterprise Value per Revenue stands at 0.666 whereas that against EBITDA is 7.089.
Stock Price History:
The Beta on a monthly basis for ARDT is 0.45, which has changed by -0.21111733 over the last 52 weeks, in comparison to a change of 0.15085125 over the same period for the S&P500. Over the past 52 weeks, ARDT has reached a high of $17.95, while it has fallen to a 52-week low of $10.10. The 50-Day Moving Average of the stock is 0.72%, while the 200-Day Moving Average is calculated to be 4.05%.
Shares Statistics:
For the past three months, ARDT has traded an average of 355.45K shares per day and 312660 over the past ten days. A total of 143.10M shares are outstanding, with a floating share count of 32.55M. Insiders hold about 77.25% of the company’s shares, while institutions hold 12.93% stake in the company. Shares short for ARDT as of 1761868800 were 2765583 with a Short Ratio of 7.78, compared to 1759190400 on 2443710. Therefore, it implies a Short% of Shares Outstanding of 2765583 and a Short% of Float of 8.3000004.
Earnings Estimates
Current recommendations for the stock of the company come from 6.0 analysts. The consensus estimate for the next quarter is $0.31, with high estimates of $0.39 and low estimates of $0.23.
Analysts are recommending an EPS of between $1.9 and $1.83 for the fiscal current year, implying an average EPS of $1.87. EPS for the following year is $1.98, with 6.0 analysts recommending between $2.29 and $1.73.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $1.66B this quarter.It ranges from a high estimate of $1.69B to a low estimate of $1.62B. As of. The current estimate, Ardent Health Inc’s year-ago sales were $1.61BFor the next quarter, 10 analysts are estimating revenue of $1.57B. There is a high estimate of $1.61B for the next quarter, whereas the lowest estimate is $1.51B.
A total of 12 analysts have provided revenue estimates for ARDT’s current fiscal year. The highest revenue estimate was $6.4B, while the lowest revenue estimate was $6.2B, resulting in an average revenue estimate of $6.33B. In the same quarter a year ago, actual revenue was $5.97BBased on 11 analysts’ estimates, the company’s revenue will be $6.65B in the next fiscal year. The high estimate is $6.78B and the low estimate is $6.44B.
